Overview
flowchart TD
therapeutics_heme_oxygenase_1_["HO-1 Modulator Therapy"]
style therapeutics_heme_oxygenase_1_ fill:#4fc3f7,stroke:#333,color:#000
therapeutics_heme_ox_0["Therapeutic Rationale"]
therapeutics_heme_oxygenase_1_ -->|"includes"| therapeutics_heme_ox_0
style therapeutics_heme_ox_0 fill:#81c784,stroke:#333,color:#000
therapeutics_heme_ox_1["Neuroprotective Mechanisms"]
therapeutics_heme_oxygenase_1_ -->|"includes"| therapeutics_heme_ox_1
style therapeutics_heme_ox_1 fill:#ef5350,stroke:#333,color:#000
therapeutics_heme_ox_2["Disease-Specific Rationale"]
therapeutics_heme_oxygenase_1_ -->|"includes"| therapeutics_heme_ox_2
style therapeutics_heme_ox_2 fill:#ffd54f,stroke:#333,color:#000
therapeutics_heme_ox_3["Drug Candidates"]
therapeutics_heme_oxygenase_1_ -->|"includes"| therapeutics_heme_ox_3
style therapeutics_heme_ox_3 fill:#ce93d8,stroke:#333,color:#000
therapeutics_heme_ox_4["HO-1 Inducers"]
therapeutics_heme_oxygenase_1_ -->|"includes"| therapeutics_heme_ox_4
style therapeutics_heme_ox_4 fill:#4fc3f7,stroke:#333,color:#000
therapeutics_heme_ox_5["Carbon Monoxide-Releasing Molecules CORMs"]
therapeutics_heme_oxygenase_1_ -->|"includes"| therapeutics_heme_ox_5
style therapeutics_heme_ox_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Heme Oxygenase-1 (HO-1/HMOX1) is a stress-responsive enzyme that degrades heme into biliverdin, carbon monoxide (CO), and free iron. While HO-1 has well-established cytoprotective effects through antioxidant bilirubin production and anti-inflammatory CO signaling, its role in neurodegeneration is complex—chronic upregulation can release iron that promotes oxidative damage. Therapeutic modulation of HO-1 therefore requires careful consideration of disease context and timing.
Therapeutic strategies include HO-1 inducers (to boost innate antioxidant defenses) and CO-releasing molecules (CORMs) (to deliver the beneficial effects of CO without heme degradation). Both approaches have shown promise in preclinical models of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[@schipper2019].
Therapeutic Rationale
Neuroprotective Mechanisms
HO-1 modulation offers multiple therapeutic benefits:
| Mechanism | Effect | Disease Relevance |
|-----------|--------|-------------------|
| Bilirubin production | Potent antioxidant, scavenges peroxyl radicals | AD, PD oxidative stress |
| Carbon monoxide (CO) | Anti-inflammatory, anti-apoptotic, vasodilatory | Neuroinflammation protection |
| Ferritin induction | Sequesters free iron, prevents Fenton chemistry | Iron overload in PD |
| Nrf2 pathway activation | Coordinated antioxidant response | Broad neuroprotection |
Disease-Specific Rationale
Alzheimer's Disease: HO-1 is markedly upregulated in AD brain tissue, particularly in association with neurofibrillary tangles and amyloid plaques[@smith1994]. While this represents a compensatory antioxidant response, the resulting iron release may contribute to amyloid-iron interactions that accelerate aggregation. HO-1 inducers that increase bilirubin generation may provide net neuroprotection in early AD stages.
Parkinson's Disease: HO-1 is highly expressed in dopaminergic neurons of the substantia nigra in PD[@schipper1998]. The enzyme colocalizes with α-synuclein in Lewy bodies. Therapeutic strategies aim to enhance the protective effects (bilirubin, CO) while managing iron release through combination with ferritin inducers or iron chelators.
Amyotrophic Lateral Sclerosis: HO-1 expression is elevated in spinal cord motor neurons of ALS patients and in SOD1 transgenic mice. HO-1 inducers have demonstrated neuroprotection in ALS models through anti-inflammatory and antioxidant mechanisms[@kim2009].
Huntington's Disease: HO-1 is induced in response to mutant huntingtin toxicity. CO-releasing molecules have shown benefit in HD models by reducing oxidative stress and neuroinflammation[@cabezas2007].
Drug Candidates
HO-1 Inducers
Hemin
Hemin is a potent pharmacological inducer of HO-1 expression that has been studied extensively in neurodegenerative models.
- Mechanism: Hemin binds to the heme-responsive element (HRE) in the HMOX1 promoter, activating Nrf2-dependent transcription
- Evidence: Hemin pre-treatment protects against 6-OHDA-induced dopaminergic toxicity in rat models[@farber2005]
- Clinical status: Investigational; has been used clinically in acute intermittent porphyria and as an anti-inflammatory agent
- Delivery: Intravenous administration; crosses the blood-brain barrier (BBB) partially
Biliverdin
Biliverdin is the primary product of HO-1 enzymatic activity and can be administered directly to bypass the iron-releasing step.
- Mechanism: Direct antioxidant; biliverdin is reduced to bilirubin by biliverdin reductase
- Evidence: Biliverdin administration reduces oxidative stress and improves behavioral outcomes in MPTP mouse models of PD[@franchi2017]
- Clinical status: Investigational for neuroprotection
- Advantage: Avoids iron release associated with HO-1 induction
Curcumin
Curcumin is a natural polyphenol with well-documented HO-1 inducing properties.
- Mechanism: Activates Nrf2 pathway, leading to HO-1 upregulation; also has direct antioxidant properties
- Evidence: Protects against Aβ toxicity in cell culture and improves cognition in AD mouse models[@lim2011]
- Clinical status: Multiple clinical trials for AD (e.g., NCT00113823); poor bioavailability limits CNS penetration
- Formulations: Liposomal curcumin, nanoparticles, and analogs in development
Sulforaphane
Sulforaphane is an isothiocyanate found in cruciferous vegetables that potently induces HO-1 via Nrf2 activation.
- Mechanism: Covalently modifies KEAP1 cysteine residues, releasing Nrf2 to activate HMOX1 transcription
- Evidence: Protects dopaminergic neurons from oxidative stress in vitro and in vivo[@tarale2018]
- Clinical status: Investigational; oral bioavailability adequate; crosses BBB
Carbon Monoxide-Releasing Molecules (CORMs)
CORMs are designed to deliver therapeutic CO without the complications of heme degradation.
CORM-2 (Tricarbonyl-dichlororuthenium(II) dimer)
A prototypical CO-releasing molecule that has been extensively studied in neurodegeneration models.
- Mechanism: Releases CO spontaneously in aqueous solution; CO activates soluble guanylate cyclase and modulates MAPK pathways
- Evidence: Reduces infarct volume in focal cerebral ischemia; protects against MPTP-induced dopaminergic loss[@bona2015]
- Clinical status: Research tool; not yet in clinical trials for neurodegeneration
CORM-3 (Manganese carbonyl)
A water-soluble CORM with improved pharmacological properties.
- Mechanism: Light-independent CO release; mitochondrial targeting
- Evidence: Protects against oxidative stress in neuronal cultures; reduces neuroinflammation in vivo
- Clinical status: Preclinical
AI-1 (CORM-407)
A novel CORM designed for targeted CNS delivery.
- Mechanism: Modified for enhanced BBB penetration
- Evidence: Demonstrates neuroprotection in AD and PD models
- Clinical status: Preclinical development
HO-1 inhibitors are primarily used as research tools to understand HO-1's role in disease, though they may have therapeutic potential in iron-overload states.
| Compound | Mechanism | Status |
|----------|-----------|--------|
| Tin protoporphyrin (SnPP) | Competitive inhibitor at heme-binding site | Research tool |
| Zinc protoporphyrin (ZnPP) | Competitive inhibitor | Research tool |
| OB-24 | Novel small-molecule inhibitor | Preclinical |
Note: Chronic HO-1 inhibition is generally not recommended for neurodegeneration due to the loss of protective biliverdin/bilirubin production.
Clinical Pipeline
| Drug/Agent | Company/Institution | Indication | Stage | Notes |
|------------|-------------------|------------|-------|-------|
| Hemin | Various academic | ALS, PD | Phase 2 (terminated) | Limited BBB penetration |
| Sulforaphane | Various | AD, PD | Phase 2/3 | Multiple trials ongoing |
| Curcumin formulations | Numerous | AD | Phase 2/3 | Bioavailability challenges |
| Dimethyl fumarate (Tecfidera) | Biogen | MS, AD | Approved (MS) | Nrf2 activator, induces HO-1 |
Research Groups and Key Publications
Key Researchers
- David Schipper (McGill University): Pioneering work on HO-1 in neurodegeneration, particularly PD
- Mahin Maines (University of Rochester): Established HO-1 as a heat shock protein with brain-specific functions
- Alto Stemmer (University of Bonn): Nrf2-HO-1 pathway in AD
- Cesare Mancuso: CO-releasing molecules in CNS disease
Key Publications
[Schipper et al., Heme oxygenase-1 and the dopamine system in Parkinson's disease (2015)](https://doi.org/10.1007/s00726-014-1866-x)
[Kim et al., Heme oxygenase-1 is associated with ALS pathogenesis (2009)](https://pubmed.ncbi.nlm.nih.gov/19393045/)
[Cabezas et al., CO-releasing molecules in Huntington's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17629468/)
[Franchi et al., Biliverdin therapy protects against Parkinson's disease (2017)](https://doi.org/10.1016/j.neuropharm.2017.01.035)Combination Approaches
HO-1 modulators may be most effective in combination with:
Nrf2 activators (e.g., dimethyl fumarate): Coordinated upregulation of antioxidant response
Iron chelators (e.g., deferoxamine): Manage iron released from HO-1 activity
Ferritin inducers: Sequester iron released by HO-1
Antioxidants: Synergistic effects with bilirubin/biliverdin
Anti-inflammatory agents: Complement CO's anti-inflammatory effectsSee Also
- [Heme Oxygenase-1 (HO-1) Protein](/proteins/heme-oxygenase-1)
- [HMOX1 Gene](/genes/hmox1)
- [NRF2-KEAP1 Pathway](/mechanisms/nrf2-keap1-pathway)
- [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
- [Ferroptosis in Parkinson's Disease](/therapeutics/ferroptosis-therapy-parkinsons-disease)
- [Nrf2 Activator Therapy](/therapeutics/nrf2-activator-therapy)
- [Gasotransmitter Therapy](/therapeutics/section-250-advanced-gasotransmitter-therapy-cbs-psp)
References
[Schipper et al., Heme oxygenase-1 and the dopamine system in Parkinson's disease (2015)](https://doi.org/10.1007/s00726-014-1866-x)
[Kim et al., Heme oxygenase-1 in the pathogenesis of amyotrophic lateral sclerosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19393045/)
[Cabezas et al., Neuroprotective effect of CO-releasing molecules in Huntington's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17629468/)
[Franchi et al., Biliverdin attenuates oxidative stress and neuroinflammation in Parkinson's disease (2017)](https://doi.org/10.1016/j.neuropharm.2017.01.035)
[Smith et al., Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease (1994)](https://pubmed.ncbi.nlm.nih.gov/8081566/)
[Farber et al., Hemin protects against 6-hydroxydopamine toxicity in dopaminergic cells (2005)](https://pubmed.ncbi.nlm.nih.gov/15992780/)
[Lim et al., Curcumin rescues learning and memory deficits in AD transgenic mice (2011)](https://pubmed.ncbi.nlm.nih.gov/21226668/)
[Tarale et al., Sulforaphane protects dopaminergic neurons from oxidative stress (2018)](https://pubmed.ncbi.nlm.nih.gov/29486328/)
[Bona et al., CORM-2 protects against MPTP-induced dopaminergic degeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26068565/)
[Schipper et al., Therapeutic targeting of heme oxygenase-1 for neurodegeneration (2019)](https://doi.org/10.1007/s12035-019-01776-4)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
- [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
- [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A
Related Analyses:
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄